A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

被引：4
|
作者：
Daver, Naval G. [1 ]
Kremyanskaya, Marina [2 ]
O'Connell, Casey [3 ]
Dao, Kim-Hien [4 ]
Oh, Stephen T. [5 ]
Gerds, Aaron T. [6 ]
Verstovsek, Srdan [1 ]
Erickson-Viitanen, Sue [7 ]
Zhou, Feng [7 ]
Assad, Albert [7 ]
Yacoub, Abdulraheem [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Univ Southern Calif, Los Angeles, CA USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Incyte Corp, Wilmington, DE USA
[8] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
353
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)
    Bose, Prithviraj
    Pemmaraju, Naveen
    Schroeder, Kurt
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [32] Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
    Harrison, Claire
    Garcia, Jacqueline S.
    Mesa, Ruben
    Somervaille, Tim
    Ritchie, Ellen K.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Verstovsek, Srdan
    Jung, Paul
    Holes, Leanne
    Masud, Abdullah
    Harb, Jason
    Hutti, Jessica E.
    Prchal, Josef T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S325
  • [33] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [34] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
  • [35] A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL)
    Forero-Torres, Andres
    Barr, Paul M.
    Diefenbach, Catherine S. Magid
    Sher, Taimur
    Schaub, Richard
    Zhou, Li
    Pulini, Jennifer
    Leopold, Lance
    Spear, Matthew A.
    Talpaz, Moshe
    Phillips, Tycel Jovelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Visualizing the efficacy of PI3K inhibitor combination treatment on tumor metabolism
    Vaidya, Manushka
    Sonzogni, Olmo
    Callahan, Cody
    Pinto, Jocelin
    Wulf, Gerburg M.
    Grant, Aaron
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis
    Rampal, Raajit
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron Thomas
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Kuykendall, Andrew Tucker
    Mesa, Ruben A.
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Harris, Morgan
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    Mascarenhas, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
    Phillips, Tycel Jovelle
    Forero-Torres, Andres
    Sher, Taimur
    Diefenbach, Catherine S. Magid
    Talpaz, Moshe
    Scherle, Peggy A.
    Schaub, Richard
    Zhou, Li
    Pulini, Jennifer
    Leopold, Lance
    Spear, Matthew A.
    Barr, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3455 - 3465
  • [40] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Stephen Couban
    Giulia Benevolo
    William Donnellan
    Jennifer Cultrera
    Steffen Koschmieder
    Srdan Verstovsek
    Gregory Hooper
    Christian Hertig
    Maneesh Tandon
    Natalie Dimier
    Vikram Malhi
    Francesco Passamonti
    Journal of Hematology & Oncology, 11
12345